These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 15031593)

  • 41. Multicenter Phase II study of cetuximab plus irinotecan in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin and fluoropyrimidines.
    Tahara M; Shirao K; Boku N; Yamaguchi K; Komatsu Y; Inaba Y; Arai T; Mizunuma N; Satoh T; Takiuchi H; Nishina T; Sakata Y
    Jpn J Clin Oncol; 2008 Nov; 38(11):762-9. PubMed ID: 18836202
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Should capecitabine replace 5-fluorouracil in the first-line treatment of metastatic colorectal cancer?
    Aguado C; García-Paredes B; Sotelo MJ; Sastre J; Díaz-Rubio E
    World J Gastroenterol; 2014 May; 20(20):6092-101. PubMed ID: 24876731
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma.
    Folprecht G; Lutz MP; Schöffski P; Seufferlein T; Nolting A; Pollert P; Köhne CH
    Ann Oncol; 2006 Mar; 17(3):450-6. PubMed ID: 16303861
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mitomycin-C and capecitabine as third-line chemotherapy in patients with advanced colorectal cancer: a phase II study.
    Lim DH; Park YS; Park BB; Ji SH; Lee J; Park KW; Kang JH; Lee SH; Park JO; Kim K; Kim WS; Jung CW; Im YH; Kang WK; Park K
    Cancer Chemother Pharmacol; 2005 Jul; 56(1):10-4. PubMed ID: 15782313
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Capecitabine/irinotecan combination regimens in colorectal cancer.
    Kerr DJ
    Oncology (Williston Park); 2002 Apr; 16(4 Suppl 3):27-9. PubMed ID: 12014865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Triplet combination of fluoropyrimidines, oxaliplatin, and irinotecan in the first-line treatment of metastatic colorectal cancer.
    Masi G; Vasile E; Loupakis F; Bursi S; Ricci S; Petrini I; Fontana A; Allegrini G; Falcone A
    Clin Colorectal Cancer; 2008 Jan; 7(1):7-14. PubMed ID: 18279572
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The role of UFT in metastatic colorectal cancer.
    Bennouna J; Saunders M; Douillard JY
    Oncology; 2009; 76(5):301-10. PubMed ID: 19299903
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation.
    Ward S; Kaltenthaler E; Cowan J; Brewer N
    Health Technol Assess; 2003; 7(32):1-93. PubMed ID: 14604497
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
    Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
    Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Oxaliplatin plus oral fluoropyrimidines in colorectal cancer.
    Grothey A; Goetz MP
    Clin Colorectal Cancer; 2004 Jun; 4 Suppl 1():S37-42. PubMed ID: 15212704
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Review of the role of CPT-11 in the treatment of colorectal cancer.
    Rougier P; Mitry E
    Clin Colorectal Cancer; 2001 Aug; 1(2):87-94. PubMed ID: 12445366
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial.
    Kabbinavar FF; Schulz J; McCleod M; Patel T; Hamm JT; Hecht JR; Mass R; Perrou B; Nelson B; Novotny WF
    J Clin Oncol; 2005 Jun; 23(16):3697-705. PubMed ID: 15738537
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Metastatic colorectal cancer: integrating irinotecan into combination and sequential chemotherapy.
    Douillard JY; Sobrero A; Carnaghi C; Comella P; Díaz-Rubio E; Santoro A; Van Cutsem E
    Ann Oncol; 2003; 14 Suppl 2():ii7-12. PubMed ID: 12810451
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.
    Jean GW; Shah SR
    Pharmacotherapy; 2008 Jun; 28(6):742-54. PubMed ID: 18503402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A randomised phase II study of irinotecan in combination with 5-FU/FA compared with irinotecan alone as second-line treatment of patients with metastatic colorectal carcinoma.
    Graeven U; Arnold D; Reinacher-Schick A; Heuer T; Nusch A; Porschen R; Schmiegel W
    Onkologie; 2007 Apr; 30(4):169-74. PubMed ID: 17396039
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The new chemotherapy of colorectal cancers].
    Taïeb J; Boige V; Ducreux M
    Presse Med; 2002 Jan; 31(3):132-8. PubMed ID: 11859739
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Second-line treatment of patients with metastatic colorectal cancer.
    Rougier P; Lepere C
    Semin Oncol; 2005 Dec; 32(6 Suppl 9):S48-54. PubMed ID: 16399432
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
    Delaunoit T; Goldberg RM; Sargent DJ; Morton RF; Fuchs CS; Findlay BP; Thomas SP; Salim M; Schaefer PL; Stella PJ; Green E; Mailliard JA
    Cancer; 2004 Nov; 101(10):2170-6. PubMed ID: 15470715
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma: final results of the Southern Italy Cooperative Oncology Group Trial 0108.
    Comella P; Natale D; Farris A; Gambardella A; Maiorino L; Massidda B; Casaretti R; Tafuto S; Lorusso V; Leo S; Cannone M
    Cancer; 2005 Jul; 104(2):282-9. PubMed ID: 15948167
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of oxaliplatin combined with 5-fluorouracil and folinic acid in the first- and second-line treatment of advanced colorectal cancer.
    Jonker D; Rumble RB; Maroun J;
    Curr Oncol; 2006 Oct; 13(5):173-84. PubMed ID: 22792014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.